Page 172 - Read Online

Neuroimmunol Neuroinflammation 2019;6:15 I http://dx.doi.org/10.20517/2347-8659.2019.019 Page 11 of 24

15. Plasma-biomarker panel for discriminating Alzheimer’s disease, Parkinson diseases, and
Frontotemporal dementia

1
2
5
3
4
Charles S. Y. Yang , Ming-Jang Chiu , Chin-Hsien Lin , Wei-Che Lin , Fu-Chi Yang , Pai-Yi Chiu ,
2
Wen-Ping Chen
6
1 MagQu Co., Ltd., Bew Taipei City 231, Taiwan
2 Department of Neurology, National Taiwan University Hospital, Taipei 100, Taiwan
3 Department of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University,
College of Medicine, Kaohsiung 833, Taiwan
4 Department of Neurology, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan
5 Department of Neurology, Show Chwan Memorial Hospital, Changhua City, Changhua County 500, Taiwan
6 MagQu LLC, Surprise, AZ, US; Huei-Chun Liu, MagQu Co., Ltd., New Taipei City 231, Taiwan

Neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson diseases (PD), and
Frontotemporal dementia (FTD) sometimes show similar change in one kind of biomarker as compared
to healthy controls. Use of individual biomarker may cause low specificity to identify the disease type. The
demand for a biomarker panel is growing to achieve a high-degree discrimination among different types of
neurodegenerative diseases. In this work, the assay technology “immunomagnetic reduction” was applied to
assay Amyloid Beta Peptide (Ab) 1-40, total Tau protein (T-Tau), phosphorylated Tau protein (p-Tau181),
a-synuclein, phosphorylated a-synuclein (pS181), TDP-43, and Neurofilament Light (NfL) in human plasma
for HC (n = 91), amnesic mild cognitive impairment (n = 41), AD (n = 35), PD with normal cognition (n =
47), PD dementia (PDD) (n = 62), and FTD (n = 25). For each kind of biomarkers, hematocrit (HC) shows
a significantly lower level as compared to disease groups. It was found that FTD shows the highest levels of
T-Tau (41.5 ± 20.5 pg/mL), p-Tau181 (6.67 ± 1.34 pg/mL), and TDP-43 (0.356 ± 0.202 pg/mL). AD shows the
highest levels of Ab1-42 (21.2 ± 7.2 pg/mL). PDD shows the highest levels of a-synuclein (4.76 ± 1.10 pg/mL)
and pS181 (12.4 ± 18.6 fg/mL). According to these data, a plasma-biomarker panel constructed with Ab1-
42, T-Tau, and a-synuclein is promising for differentiating AD, PD, and FTD.

16. Circulating circular RNAs as biomarkers in the acute phase of ischemic stroke

1
Lei Zuo , Hong-Hong Yao 2

1 Department of Neurology, Affiliated ZhongDa Hospital, School of Medicine, Southeast University, Nanjing
210009, Jiangsu, China
2 Department of Pharmacology, Medical School of Southeast University, Nanjing 210009, Jiangsu, China

Currently, there are no valuable blood-based biomarkers that can be used for diagnosing acute ischemic
stroke (AIS) and predicting stroke outcomes. circRNAs show promise as stroke biomarkers because
of their participation in various pathophysiological processes associated with stroke and stability in
peripheral blood. To explore circulating circRNAs associated with AIS, their utility as an early diagnostic
marker and their significance in predicting stroke outcomes, a circRNA microarray was used to identify
differentially expressed circulating circRNAs in a discovery cohort of three patients with AIS and three
matched healthy control subjects (HCs). Validation was performed in an independent validation cohort (36
patients with AIS and 36 matched HCs) by quantitative real-time polymerase chain reaction (qRT-PCR).
The replication cohort (200 patients with AIS and 100 HCs) was used for large sample verification, and the